Hospitals: Proposed Inpatient Fiscal 2023 Pay Drop Unacceptable

Hospital officials are upset that, when taken in its entirety, the proposed inpatient pay rule would amount to a pay cut -- and they say even the pay update pales in comparison to overall inflation. Fiscal 2023 is not the time to cut back on pay that helps hospitals cover the cost of uncompensated care and caring for the uninsured during the pandemic, they assert. CMS’ fiscal 2023 hospital inpatient proposed rule includes a 3.2% rate increase for inpatient prospective...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 04/28/2022
CMS Volume: 
Vol. 25, No. 17
Author: 

Over One In Four Long Term Care Facilities Report Workforce Shortages

Long term care workforce shortages have intensified significantly as a result of the COVID-19 pandemic, according to a new report, which finds that nearly of a quarter of facilities nationwide have reported shortages in nursing staff since the start of 2022. The new report, which consumer group Seniorly conducted using CMS nursing home staffing data from 2020-2022, found the number of facilities that experienced a worker shortage rose from 11% in May 2020 to as high as 23% in January...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 04/28/2022
CMS Volume: 
Vol. 25, No. 17
Author: 

Groups Urge FDA To Act Fast On Menthol Ban After WH Clears Proposal

The White House on Thursday (April 21) completed its review of two proposed rules from FDA that would ban menthol in cigarettes and prohibit characterizing flavors in cigars, prompting 77 medical, public health and tobacco control organizations to urge the agency to move forward on the rules “without delay.” FDA indicated in its Fall 2021 unified agenda that it intends to publish the proposals this month. The White House Office of Management and Budget began reviewing the rules in February...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 04/29/2022
FDA Volume: 
Vol. 28, No. 17
Author: 

FDA Aims To Study How Rx Drug Promo Affects Patient, Physician Choices

FDA hopes to conduct a study assessing how prescription drug promotion, and in particular information about a drug’s efficacy, risks and adherence, affects medication decisions by consumers and providers, the agency announced Friday (April 22). The proposed study will focus on medications for type 2 diabetes and psoriasis. There is currently little information on the tradeoffs patients make when considering drug product characteristics and how the tradeoffs could potentially differ from the tradeoffs made by physicians, FDA says in its...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 04/29/2022
FDA Volume: 
Vol. 28, No. 17
Author: 

FDA Unveils Draft NAC Policy, Supplement Orgs Urge Permanent Solution

FDA unveiled a proposed enforcement discretion policy saying it won’t take action against dietary supplements containing N-acetyl-L-cysteine (NAC), as long as they’re not adulterated or misbranded. Dietary supplement groups say FDA’s proposal offers a short-term compromise, but they add there still needs to be a long-term solution to prevent agency overreach and ensure consumers have access to NAC-containing supplements in the future. The agency is reviewing data on NAC, which is approved as a drug ingredient and under law is...
Article Type: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 04/29/2022
FDA Volume: 
Vol. 28, No. 17
Author: 


ICER Proposes Creating Ultra-Rare Orphan Drug Class

Congress should consider creating a new category of “ultra-rare” drugs, boost incentives for those drugs, and take away some of the incentives for so-called partial orphan drugs, according to policy reforms explored by the Institute for Clinical and Economic Review in an April 7 white paper . ICER President Stephen Pearson said he worries that evidence requirements for orphan drugs are weakening, and it’s not clear that the health care system can afford orphan drugs as they become more common...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 04/25/2022
IDP Volume: 
Vol. 5, No. 17
Author: 


Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.